AUZ454

featured

WARNING: This product is for research use only, not for human or veterinary use.

Description:AUZ454 is a potent and selective Type II FLT3 inhibitor.AUZ454is able to override drug resistance that less potent "type I" inhibitors and "type II" first-generation FLT3 inhibitors cannot. Constitutively activated mutant FLT3 has emerged as a promising target for therapy for the subpopulation of acute myeloid leukemia (AML) patients who harbor it. The small molecule inhibitor, PKC412, targets mutant FLT3 and is currently in late-stage clinical trials. However, the identification of PKC412-resistant leukemic blast cells in the bone marrow of AML patients has propelled the development of novel and structurally distinct FLT3 inhibitors that have the potential to override drug resistance and more efficiently prevent disease progression or recurrence.

Price and Availability

AUZ454, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure

Theoretical Analysis

MedKoo Cat#: 406217Name: AUZ454CAS#: 853299-07-7Chemical Formula: C24H26F3N7O2Exact Mass: 501.21001Molecular Weight: 501.50415Elemental Analysis: C, 57.48; H, 5.23; F, 11.36; N, 19.55; O, 6.38

Synonym:AUZ454; AUZ 454; AUZ-454; K03861; K-03861; K 03861

IUPAC/Chemical Name:1-(4-((2-aminopyrimidin-4-yl)oxy)phenyl)-3-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)urea

InChi Key:PWDLXPJQFNVTNL-UHFFFAOYSA-N

InChi Code:InChI=1S/C24H26F3N7O2/c1-33-10-12-34(13-11-33)15-16-2-3-18(14-20(16)24(25,26)27)31-23(35)30-17-4-6-19(7-5-17)36-21-8-9-29-22(28)32-21/h2-9,14H,10-13,15H2,1H3,(H2,28,29,32)(H2,30,31,35)

SMILES Code:O=C(NC1=CC=C(CN2CCN(C)CC2)C(C(F)(F)F)=C1)NC3=CC=C(OC4=NC(N)=NC=C4)C=C3

Technical Data

Additional Information

References

1: Weisberg E, Roesel J, Furet P, Bold G, Imbach P,Flörsheimer A, Caravatti G, Jiang J, Manley P, Ray A, Griffin JD.Antileukemic Effects of Novel First- and Second-Generation FLT3Inhibitors: Structure-Affinity Comparison. Genes Cancer. 2010Oct;1(10):1021-32. doi: 10.1177/1947601910396505. PubMed PMID: 21779428;PubMed Central PMCID: PMC3092267.